Summit Therapeutics (SMMT) Research & Development (2019 - 2026)

Summit Therapeutics has reported Research & Development for 8 years, with the latest figure at $132.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 158.69% year-over-year to $132.6 million; the trailing twelve-month figure through Mar 2026 stood at $619.0 million (up 261.65% YoY), and the FY2025 full-year result was $537.7 million, up 256.6% from the prior year.
• Research & Development for Q1 2026 stood at $132.6 million, down from $147.3 million in the prior quarter.
• The five-year high for Research & Development was $208.0 million in Q2 2025, with the low at $5.4 million in Q4 2022.
• Historically, Research & Development has averaged $54.9 million across 5 years, with a median of $30.8 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development tumbled 76.69% — and 2025, when it soared 575.44%.
• Summit Therapeutics' Research & Development stood at $5.4 million in 2022, then soared by 360.71% to $24.8 million in 2023, then surged by 107.07% to $51.4 million in 2024, then surged by 186.66% to $147.3 million in 2025, then decreased by 9.96% to $132.6 million in 2026.
• The last three Research & Development figures came in at $132.6 million (Q1 2026), $147.3 million (Q4 2025), and $131.1 million (Q3 2025), per Business Quant data.